Healthcare Industry News: drug-eluting stent
News Release - September 4, 2007
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus StentWhile no significant differences were found, results showed CYPHER(R) Stent had lower mortality and heart attack rates
VIENNA, Austria, Sept. 4 (HSMN NewsFeed) -- A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER® Sirolimus-eluting Coronary Stent to the Taxus Stent showed no statistically significant differences in safety outcomes between the two drug- eluting stents. The authors of the analysis, presented today at the European Society of Cardiology Congress 2007 (ESC Congress 2007), also reported that in the CYPHER® Stent arm there were numerically lower rates of cardiac mortality, blood clots and heart attack rates than in the Taxus Stent arm, although these differences did not reach statistical significance.
"In this analysis of head-to-head randomized controlled trial data, both drug-eluting stents yielded similar safety outcomes and the CYPHER® Stent presented safety rates in some areas that were numerically lower," Giulio Guagliumi, M.D., from the Ospedale Riuniti Di Bergamo in Bergamo, Italy, who presented the results on behalf of the REALITY Trial investigators.
The cardiac death rates were 1.6 percent for the CYPHER® Stent and 4.7 percent for the Taxus Stent (p=0.14). The rate of Q-wave myocardial infarction (heart attacks that involve the full thickness of the heart wall) was 0.0 percent for the CYPHER® Stent and 1.6 percent for the Taxus Stent (p=0.25). In addition, the rates of non-Q wave myocardial infarctions (heart attacks that do not involve the full thickness of the heart wall) were 4.8 percent for the CYPHER® Stent and 5.2 percent for the Taxus Stent (p=1.00). None of these numerical differences in favor of the CYPHER® Stent reached statistical significance.
Both drug-eluting stents were also equivalent in terms of major adverse cardiac events (MACE), which in this study were defined to include cardiac deaths, Q-wave myocardial infarctions, non-Q wave myocardial infarctions, emergent bypass surgery and target lesion revascularizations (a subsequent procedure to reopen an artery). The MACE rate for the CYPHER® Stent was 15.5 percent while the MACE rate for the Taxus Stent was 14.1 percent (p=0.77).
At the World Congress of Cardiology 2006, the REALITY Trial investigators reported a stent thrombosis rate for the Taxus Stent that was significantly higher than the rate for the CYPHER® Stent in the overall patient population (2.5 percent for the Taxus Stent versus 0.9 percent for the CYPHER® Stent; p log-rank=0.02). While the difference between the protocol-defined stent thrombosis rate for each drug-eluting stent in the diabetic patient subgroup did not reach statistical significance, the rate for the Taxus Stent remained numerically higher than the rate for the CYPHER® Stent (3.1 percent for the Taxus Stent versus 1.1 percent for the CYPHER® Stent; p log-rank=0.16).
These numerically lower rates of cardiac death, Q-wave myocardial infarction and stent thrombosis favoring the CYPHER® Stent were also seen in diabetic patients who required insulin therapy.
"Diabetic patients remain one of the most complex patient populations to treat for coronary artery disease," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. "This analysis provides additional and relevant information to doctors regarding the long- term efficacy and safety outcomes in diabetic patients treated with either the CYPHER® Stent or the Taxus Stent."
The analysis involved 375 diabetic patients, which represented 28 percent of the patients enrolled in the REALITY Trial. The REALITY Trial was comprised of 1,386 moderately complex patients from 90 centers in Europe, Latin America and Asia. These patients were randomly selected to receive either the CYPHER® Stent or the Taxus Stent. In the end, the CYPHER® Stent was used in 684 patients and 970 artery blockages, while the Taxus Stent was used in 669 patients and 941 artery blockages.
Cordis Corporation sponsored the REALITY Trial.
About the CYPHER® Stent
The CYPHER® Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER® Stent in a broad range of patients.
Developed and manufactured by Cordis Corporation, the CYPHER® Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.
For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.
*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune®. Rapamune is a trademark of Wyeth Pharmaceuticals.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.